

Pembrolizumab KEYNOTE-040

PRELIMINARY SCORE

CURATIVE



NON-CURATIVE



ADJUSTMENTS

Quality of life



Serious and disabling adverse effects



Other adjustments



Pembrolizumab KEYNOTE-040

FINAL SCORE

CURATIVE




Overall Survival / Disease-Free Survival / Pathological Complete Response

NON-CURATIVE




Overall Survival



Progression-Free Survival



Non-inferiority (Improved Quality of Life or Reduced Adverse Events) / Response Rate



Overall Response Rate / Duration of Response

Overall Survival / Disease-Free Survival / Pathological Complete Response

INFORMATION

Tumour type: Head and neck cancer
 Therapeutic Indication: Recurrent or metastatic SCCHN in adults whose tumours express PD-L1 with a $\geq 50\%$ TPS and progressing on or after platinum-containing ChT
 Experimental Arm: Pembrolizumab
 Control Arm: Standard of care (methotrexate, docetaxel or cetuximab)



